A nssessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach - The albi grade

Journal of Clinical Oncology

Volumn 33, Issue 6, 2015, Pages 550-558

  Johnson, Philip J ^a,b   Berhane, Sarah ^a   Kagebayashi, Chiaki ^g   Satomura, Shinji ^h   Teng, Mabel ^c   Reeves, Helen L ^d   O'Beirne, James ^e   Fox, Richard ^f   Skowronska, Anna ^f   Palmer, Daniel ^a,b   Yeo, Winnie ⁱ   Mo, Frankie ⁱ   Lai, Paul ⁱ   Iñarrairaegui, Mercedes ^j   Chan, Stephen L ⁱ   Sangro, Bruno ^j   Miksad, Rebecca ⁱ   Tada, Toshifumi ^k   Kumada, Takashi ^k   Toyoda, Hidenori ^k  

^a Department of Molecular and Clinical Cancer Medicine ^*  (United Kingdom)

^b CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d FREEMAN HOSPITAL   (United Kingdom)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g Wako Life Sciences   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^j INSTITUTO DE SALUD CARLOS III   (Spain)

^k OGAKI MUNICIPAL HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; SORAFENIB; SERUM ALBUMIN;

ADULT; ADVANCED CANCER; AGED; ALBUMIN BILIRUBIN MODEL; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHILD PUGH SCORE; CHINA; CHRONIC LIVER DISEASE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM DISEASE ASSESSMENT; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPAIN; UNITED KINGDOM; UNITED STATES; BIOLOGICAL MODEL; BLOOD; CANCER GRADING; CANCER STAGING; COHORT ANALYSIS; LIVER; LIVER TUMOR; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

AGED; BILIRUBIN; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM GRADING; NEOPLASM STAGING; SERUM ALBUMIN;

EID: 84923163518     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.9151     Document Type: Article

References (30)

1. Simonetti RG, Cammá C, Fiorello F, et al: Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 36:962-972, 1991
2. Fattovich G, Pantalena M, Zagni I, et al: Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: A cohort study of 297 patients. Am J Gastroenterol 97:2886-2895, 2002
3. Child CG, Turcotte JG: Surgery and portal hypertension. Major Probl Clin Surg 1:1-85, 1964
4. Pugh RN, Murray-Lyon IM, Dawson JL, et al: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646-649, 1973
5. van Dam GM, Gips CH, Reisman Y, et al: Major clinical events, signs and severity assessment scores related to actual survival in patients who died from primary biliary cirrhosis: A long-term historical cohort study. Hepatogastroenterology 46:108-115, 1999
6. Shetty K, Rybicki L, Carey WD: The Child- Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology 25:1049-1053, 1997
7. Durand F, Valla D: Assessment of prognosis of cirrhosis. Semin Liver Dis 28:110-122, 2008
8. Johnson PJ, Williams R: Cirrhosis and the aetiology of hepatocellular carcinoma. J Hepatol 4:140-147, 1987
9. Johnson PJ, Berhane S, Satomura S, et al: An international collaborative study assessing the role of aetiology and stage in survival in HCC: Implications for screening. Presented at International Liver Congress London, European Association for the Study of the Liver, London, United Kingdom, April 9-13, 2014
10. Llovet JM, Brú C, Bruix J: Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 19:329-338, 1999
11. Del Priore G, Zandieh P, Lee MJ: Treatment of continuous data as categoric variables in obstetrics and gynecology. Obstet Gynecol 89:351-354, 1997
12. Royston P, Altman DG, Sauerbrei W: Dichotomizing continuous predictors in multiple regression: A bad idea. Stat Med 25:127-141, 2006
13. Toyoda H, Kumada T, Osaki Y, et al: Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol 4:1528-1536, 2006
14. Toyoda H, Kumada T, Kiriyama S, et al: Impact of surveillance on survival of patients with initial hepatocellular carcinoma: A study from Japan. Clin Gastroenterol Hepatol 4:1170-1176, 2006
15. Chan SL, Mo FK, Johnson PJ, et al: Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol 26:340-347, 2011
16. Dyson J, Jaques B, Chattopadyhay D, et al: Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 60:110-117, 2014
17. Johnson PJ, Qin S, Park JW, et al: Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study. J Clin Oncol 31:3517-3524, 2013
18. Cheng AL, Kang YK, Lin DY, et al: Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial. J Clin Oncol 31:4067-4075, 2013
19. Liver Cancer Study Group of Japan: The General Rules for the Clinical and Pathological Study of Primary Liver Cancer (English ed). Tokyo, Japan, Kanehara & Co, 2003
20. Taktak A, Eleuteri A, Lake S, et al: Evaluation of prognostic models: Discrimination and calibration performance. Comput Intell Med 2007
21. Newson R: Confidence intervals for rank statistics: Somers' D and extensions. Stata J 6:309, 2006
22. Newson RB: Comparing the predictive powers of survival models using Harrell's C or Somers' D. Stata J 10:339, 2010
23. D'Amico G, Garcia-Tsao G, Pagliaro L: Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 44:217-231, 2006
24. Fox R, Berhane S, Teng M, et al: Biomarker-based prognosis in hepatocellular carcinoma: Validation and extension of the BALAD model. Br J Cancer 110:2090-2098, 2014
25. Durand F, Valla D: Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol 42:S100-S107, 2005 (suppl)
26. Botta F, Giannini E, Romagnoli P, et al: MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: A European study. Gut 52: 134-139, 2003
27. Bruix J, Sherman M, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: An update. Hepatology 53: 1020-1022, 2011
28. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 42:1208-1236, 2005
29. Nankivell BJ: Creatinine clearance and the assessment of renal function. Aust Prescr 24:15-17, 2001
30. Miksad RA, Cohn AL, El-Khoueiry AB, et al: Use of staging and scoring systems in hepatocellular carcinoma (HCC): Lessons from U.S. regional analysis of the GIDEON registry. J Clin Oncol 32, 2014 (suppl 3; abstr 323)